A therapy that retrains the body’s immune system to fight cancer has provoked excitement after more than 90% of terminally ill patients reportedly went into remission.
White blood cells were taken from patients with leukaemia, modified in the lab and then put back.
But the data has not been published or reviewed and two patients are said to have died from an extreme immune response.
Experts said the trial was exciting, but still only “a baby step.”
The news bubbled out of the American Association for the Advancement of Science’s annual meeting in Washington DC.
The lead scientist, Prof Stanley Riddell from the Fred Hutchinson Cancer Research Centre in Seattle, said all other treatments had failed in these patients and they had only two-to-five months to live.
He told the conference that: “The early data is unprecedented.”
In the trial, cells from the immune system called killer t-cells were taken out of dozens of patients. The cells normally act like bombs destroying infected tissue.
The researchers genetically modified the t-cells to engineer a new targeting mechanism – with the technical name of chimeric antigen receptors – to target acute lymphoblastic leukaemia.
Prof Riddell told the BBC: “Essentially what this process does is, it genetically reprograms the T-cell to seek out and recognise and destroy the patient’s tumour cells.
“[The patients] were really at the end of the line in terms of treatment options and yet a single dose of this therapy put more than ninety percent of these patients in complete remission where we can’t detect any of these leukaemia cells.”
But one cancer expert told me they still felt in the dark on the full significance of the study, as the data is not available.
Learn more: Excitement at new cancer treatment
The Latest on: Cancer immunotherapy
via Google News
The Latest on: Cancer immunotherapy
- Roswell Park, Wilmot Cancer Institute Collaborate on First Large Study of Immunotherapy in Black Cancer Patientson April 21, 2021 at 3:00 am
A new collaboration will help oncologists learn whether Black and white cancer patients respond differently to a game-changing ...
- New hope against a rare, incurable eye canceron April 20, 2021 at 7:50 am
A cutting-edge experimental drug cuts nearly in half the risk of death among patients with a rare but aggressive cancer of the eye, new clinical trial data show.
- Lineage Stock Gains After Licensing Pact With Immunomic Therapeutics For Cancer Immunotherapy Platformon April 20, 2021 at 7:23 am
Lineage Cell Therapeutics Inc (NYSE: LCTX) has entered into a worldwide license and development collaboration agreement with a privately-held Immunomic Therapeutics Inc (ITI) to manufacture and ...
- Lineage Announces Worldwide License Agreement With Immunomic Therapeutics for an Allogeneic Cell-Based Cancer Immunotherapy Based on Its VAC Platformon April 20, 2021 at 7:00 am
Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel cell transplants for ...
- First Immunotherapy for Initial Treatment of Gastric Cancer Approvedon April 19, 2021 at 4:07 pm
Nivolumab, marketed under the name Opdivo, led to a 29% reduced risk of death when combined with certain chemotherapies for gastric cancers.
- Society for Immunotherapy of Cancer Launches Online Seminar Series on Advanced Topics in Immuno-Oncologyon April 19, 2021 at 6:35 am
The Society for Immunotherapy of Cancer (SITC) is pleased to offer a highly anticipated series of live online seminars to address key questions in ...
- First FDA-approved Immunotherapy For First Treatment Of Gastric Canceron April 19, 2021 at 3:35 am
In a statement, the regulator said the approval is for the first-line treatment of patients with advanced or metastatic gastric cancer, gastroesophageal junction cancer and esophageal adenocarcinoma.
- FDA approves immunotherapy for first-line treatment of advanced gastric canceron April 16, 2021 at 10:04 am
Today, the U.S. Food and Drug Administration approved Opdivo (nivolumab), in combination with certain types of chemotherapy, for the initial treatment of patients with advanced or metastatic gastric ...
- Mixed Results for Immunotherapy in Metastatic Prostate Canceron April 11, 2021 at 5:02 pm
An immunotherapy combination for metastatic castration-resistant prostate cancer (mCRPC) failed to hit a response target but still exceeded historical results, a small prospective study showed. Ten of ...
- Genes and immune cells predict immunotherapy success in bladder canceron April 9, 2021 at 7:24 am
Sets of genes associated with resistance to immunotherapy in patients with metastatic urothelial cancer of the bladder have been identified and validated by researchers at Mount Sinai. In a study ...
via Bing News